DK2693216T3 - PROCEDURE FOR DIAGNOSIS OR PREDIAGNOSIS OF A BETA AMYLOIDOPATHY - Google Patents
PROCEDURE FOR DIAGNOSIS OR PREDIAGNOSIS OF A BETA AMYLOIDOPATHY Download PDFInfo
- Publication number
- DK2693216T3 DK2693216T3 DK13190419.5T DK13190419T DK2693216T3 DK 2693216 T3 DK2693216 T3 DK 2693216T3 DK 13190419 T DK13190419 T DK 13190419T DK 2693216 T3 DK2693216 T3 DK 2693216T3
- Authority
- DK
- Denmark
- Prior art keywords
- abcc1
- gluc
- disease
- transporter
- cerebral
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000003745 diagnosis Methods 0.000 title description 6
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 claims description 51
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims description 35
- 230000002490 cerebral effect Effects 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 108010078791 Carrier Proteins Proteins 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- ZPVSFHWMXABGPU-UHFFFAOYSA-N 4-nitroquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=NC2=C1 ZPVSFHWMXABGPU-UHFFFAOYSA-N 0.000 claims description 2
- PIZUVEAJMMIWGH-UHFFFAOYSA-N 5,7-dimethyl-2-(methylamino)-4-(pyridin-3-ylmethyl)-1,3-benzothiazol-6-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CC1=C(O)C(C)=C2SC(NC)=NC2=C1CC1=CC=CN=C1 PIZUVEAJMMIWGH-UHFFFAOYSA-N 0.000 claims description 2
- 229930195730 Aflatoxin Natural products 0.000 claims description 2
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 claims description 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 claims description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000005409 aflatoxin Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 2
- 229930182480 glucuronide Natural products 0.000 claims description 2
- 150000008134 glucuronides Chemical class 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims description 2
- 239000005445 natural material Substances 0.000 claims description 2
- 229950009829 prasterone sulfate Drugs 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- OGRXKBUCZFFSTL-UHFFFAOYSA-N 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol Chemical compound O=NN(C)CCCC(O)C1=CC=CN=C1 OGRXKBUCZFFSTL-UHFFFAOYSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 31
- 230000002950 deficient Effects 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 15
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 230000004770 neurodegeneration Effects 0.000 description 13
- 208000015122 neurodegenerative disease Diseases 0.000 description 13
- 230000032258 transport Effects 0.000 description 12
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 11
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 11
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 11
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 210000002987 choroid plexus Anatomy 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- -1 nitro, sulfonyl Chemical group 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 208000032859 Synucleinopathies Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000005110 aryl thio group Chemical group 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- RVBRTNPNFYFDMZ-SPIKMXEPSA-N thiethylperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 RVBRTNPNFYFDMZ-SPIKMXEPSA-N 0.000 description 5
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 4
- 229960004869 thiethylperazine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000040811 transporter activity Human genes 0.000 description 3
- 108091092194 transporter activity Proteins 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
- 101150014554 TARDBP gene Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000006061 fatal familial insomnia Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000007111 proteostasis Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 102000041092 ABC transporter family Human genes 0.000 description 1
- 108091060858 ABC transporter family Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000006611 pharmacological activation Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| EP11755294.3A EP2614060B1 (de) | 2010-09-07 | 2011-08-30 | Thiethylperazin zur behandlung einer beta-amyloidopathie oder alpha-synucleopathie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2693216T3 true DK2693216T3 (en) | 2019-01-14 |
Family
ID=44645670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13190419.5T DK2693216T3 (en) | 2010-09-07 | 2011-08-30 | PROCEDURE FOR DIAGNOSIS OR PREDIAGNOSIS OF A BETA AMYLOIDOPATHY |
| DK11755294.3T DK2614060T3 (da) | 2010-09-07 | 2011-08-30 | Thiethylperazin til behandlung af en beta-amyloidopati eller alpha-synukleopati |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11755294.3T DK2614060T3 (da) | 2010-09-07 | 2011-08-30 | Thiethylperazin til behandlung af en beta-amyloidopati eller alpha-synukleopati |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (enExample) |
| EP (3) | EP3097914A3 (enExample) |
| JP (2) | JP6084924B2 (enExample) |
| CN (2) | CN103237802B (enExample) |
| BR (1) | BR112013005472A2 (enExample) |
| CA (2) | CA2870626C (enExample) |
| DE (2) | DE102010062810B4 (enExample) |
| DK (2) | DK2693216T3 (enExample) |
| ES (2) | ES2605705T3 (enExample) |
| MX (1) | MX357521B (enExample) |
| PL (2) | PL2614060T3 (enExample) |
| RU (2) | RU2016118021A (enExample) |
| WO (1) | WO2012031941A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017301966B2 (en) | 2016-07-25 | 2022-09-22 | TauRx Therapeutics Management Ltd | Administration and dosage of diaminophenothiazines |
| EP3826639B1 (en) | 2018-07-26 | 2024-08-21 | WisTa Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
| EP4121546A1 (en) * | 2020-03-16 | 2023-01-25 | Doublerainbow Biosciences Inc. | Etoposide glycosides, methods of making, and uses thereof as an anti-cancer drug |
| EP4460311A1 (en) * | 2022-01-04 | 2024-11-13 | Immungenetics AG | Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia |
| CA3268498A1 (en) * | 2022-10-18 | 2024-04-25 | Immungenetics Ag | IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (enExample) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| DK1470818T3 (da) * | 2003-04-25 | 2006-11-20 | Neuro3D | Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| HUE030621T2 (en) * | 2006-07-11 | 2017-05-29 | Wista Lab Ltd | Methods for the synthesis and / or purification of diaminophenothiazinium compounds |
| ES2394377T3 (es) * | 2006-11-10 | 2013-01-31 | Cara Therapeutics, Inc. | Amidas de péptidos sintéticos |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| PT2282779E (pt) * | 2008-04-29 | 2013-05-28 | Pharnext | Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular |
| LT2282778T (lt) * | 2008-04-29 | 2017-06-26 | Pharnext | Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją |
| EP2429530B1 (en) * | 2009-05-14 | 2018-11-07 | The General Hospital Corporation | (s)-meclizine for treating ischaemia-reperfusion injury |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krohn et al. | Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice | |
| DK2693216T3 (en) | PROCEDURE FOR DIAGNOSIS OR PREDIAGNOSIS OF A BETA AMYLOIDOPATHY | |
| Walker et al. | Corruption and spread of pathogenic proteins in neurodegenerative diseases | |
| JP2016028064A (ja) | 診断用抗体アッセイ | |
| Schultz et al. | Levels of retinal IAPP are altered in Alzheimer's disease patients and correlate with vascular changes and hippocampal IAPP levels | |
| Asuni et al. | Modulation of amyloid precursor protein expression reduces β‐amyloid deposition in a mouse model | |
| WO2019074840A1 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES | |
| JP5713977B2 (ja) | 血液内アミロイドβ抗体に特異的に結合する新規なＡβ２２（ｐＥ）−４２ペプチドを有効成分として含む痴呆症診断用キット | |
| AU2023346185A1 (en) | Thiazole derivatives as tau aggregation inhibitors | |
| ES2358661B2 (es) | Utilización del gambierol para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide. | |
| Allsop | The role of amylin in Alzheimer's disease | |
| JP2008530999A (ja) | ミクログリア促進アミロイド形成のアッセイ | |
| Best et al. | Running title: Gamma secretase inhibition in the rat. | |
| Albay III | Characterization of a pathogenic conformation of amyloid immunoreactivity in Alzheimer's Disease and Cerebral Amyloid Angiopathy | |
| Munoz-Montesino et al. | https://www. jbc. org/cgi/doi/10.1074/jbc. RA120. 014738 The latest version is at | |
| KR20120098064A (ko) | 워트마닌 또는 그 유사체를 유효성분으로 함유하는 당뇨병성 신증 개선 및 치료용 약학적 조성물 |